[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-infection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,81,108,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100410437","phase-1-hyperpolarized-129xe-mr-imaging-of-lung-function-in-healthy-volunteers-and-subjects-with-pulmonary-disease-100410437",false,"NCT04624490","Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","Inclusion Criteria:\n\nHealthy Volunteers:\n\n* Subject has no diagnosed pulmonary conditions\n* Ability to read and understand English or Spanish\n\nSubjects with Lung Disease:\n\n* Subject has a diagnosis of pulmonary dysfunction made by a physician\n* No acute worsening of pulmonary function in the past 30 days\n* Ability to read and understand English or Spanish\n\nExclusion Criteria:\n\n* MRI is contraindicated based on responses to MRI screening questionnaire\n* Subject is pregnant or lactating\n* Subject does not fit into 129Xe vest coil used for MRI\n* Subject cannot hold his\u002Fher breath for 15-16 seconds\n* Subject deemed unlikely to be able to comply with instructions during imaging\n* Oxygen saturation \\\u003C88% on room air or with supplemental oxygen\n* Cognitive deficits that preclude ability to provide consent\n* Institutionalization",true,"ALL","3 Years",{"count":19,"type":20},260,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.",[26,27,28,29,30,31,32],"Asthma","COPD","Interstitial Lung Disease","Cystic Fibrosis","Pulmonary Hypertension","Pulmonary Infection","Other Lung Disease",[34],"Hyperpolarized 129Xe MRI","RECRUITING","2026-04-30",{"date":38,"type":39},"2026-05-06","ACTUAL",{"date":41,"type":39},"2020-11-02",{"date":43,"type":20},"2028-10-26",{"name":45,"class":46},"Mario Castro, MD, MPH","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100623358","phase-4-remimazolam-for-bronchoscopy-in-high-risk-patients-100623358","NCT07395596","Remimazolam for Bronchoscopy in High-Risk Patients","A Prospective, Randomized Controlled Clinical Study of the Effect of Remimazolam on the Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy","Inclusion Criteria:\n\n* ASA Class Ⅲ - Ⅳ\n* Scheduled for elective painless bronchoscopy -\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who are uncooperative（e.g. due to mental illness）\n* Patients who are on chronic use of opioids, benzodiazepine - class hypnotics, or antidepressants\n* Patients with a history of allergy to the anesthetics used\n* Patients who are anticipated to have a difficult airway\n* Body mass index（BMI）\\\u003C18.5kg\u002Fm² or \\>30kg\u002Fm²\n* Preoperative oxygen saturation \\\u003C92% while breathing room air\n* Other：Patients who are deemed by the investigator to be unsuitable for participation in this trial","18 Years",{"count":57,"type":20},360,[59],"PHASE4","Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, due to its disadvantages, such as respiratory and circulatory depression, we have introduced a novel approach combining remimazolam for sedation. The aim is to investigate whether this new regimen, compared to traditional propofol-based sedation, can reduce the incidence of hypoxia, minimize circulatory depression, and lead to faster postoperative awakening and recovery. Additionally, we hope to observe fewer adverse events, such as perioperative nausea and vomiting, excessive secretions, dizziness, and chills.",[31,62,63,64,65],"Pulmonary Nodule","Phthisis","Endotracheal Tumour","Lymphadenectasis",[67,68,69,70],"hypoxia","remimazolam","propofol","fiberoptic bronchoscopy","2026-02-21",{"date":73,"type":39},"2026-02-24",{"date":75,"type":39},"2026-02-09",{"date":77,"type":20},"2026-12",{"name":79,"class":46},"First Affiliated Hospital of Zhejiang University",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100622858","the-efficacy-and-safety-of-the-supraglottic-oxygenation-via-nasotracheal-intubation-for-deep-sedation-fiberoptic-bronchoscopy-100622858","NCT07389083","The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy","The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation Reduce the Incidence of Hypoxia in Patients Undergoing Sedated Fiberoptic Bronchoscopy.","Inclusion Criteria:\n\n* Undergoing fiberoptic bronchoscopy under deep sedation.\n* Written informed consent obtained from the patient or their legal representative.\n* Clear understanding of, and voluntary participation in, the study, with informed-consent form signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 30 kg\u002Fm²\n* Previous history of abnormal recovery from anesthesia\u002Fsurgery\n* History of recurrent epistaxis, nasal bone fracture, nasal polyps, or sinus surgery\n* Chronic use of opioid analgesics, benzodiazepine hypnotics, or antidepressant medications\n* Known allergy to any of the anesthetic agents employed\n* Anticipated difficult airway\n* Increased intracranial pressure\n* Active upper-respiratory-tract infection of the oral, nasal, or pharyngeal regions\n* Severe cardiac insufficiency (functional capacity \\\u003C 4 METs)\n* Severe renal failure requiring dialysis prior to surgery\n* Pre-operative oxygen saturation on room air \\\u003C 92 %\n* Any condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial",{"count":89,"type":20},50,[91],"NA","Bronchoscopy is now widely used for the diagnosis and treatment of various respiratory diseases. However, the procedure is highly stimulating and provokes a strong stress response; because the airway is shared, patients are prone to hypoxia. With the growing emphasis on comfortable care, demand for anesthesia during bronchoscopy has increased. Deep sedation is the most common approach, but when administered in the supine position it often causes the tongue base to fall back. Both nasopharyngeal and oropharyngeal airways can relieve this obstruction, yet neither connects seamlessly to an oxygen supply line, resulting in insufficient oxygen delivery.We therefore replaced the nasopharyngeal airway with a wired endotracheal tube (size 4.0 or 4.5) inserted via the nose. This thinner tube couples easily to an oxygen line or ventilator circuit, partially relieves airway obstruction, and allows ample supraglottic oxygenation. The present study was designed to evaluate the feasibility and safety of this modified oxygen-delivery method in patients undergoing deep sedation for bronchoscopy.",[94,62,31],"Hypoxia",[70,94,96,97,98,99],"Deep sedation","supine position","tongue-base fallback","supraglottic oxygenation","2026-01-28",{"date":102,"type":39},"2026-02-05",{"date":104,"type":39},"2025-12-28",{"date":106,"type":20},"2026-03-30",{"name":79,"class":46},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":5},"100540625","phase-2-infusion-of-prostacyclin-vs-placebo-for-72-hours-in-mechanically-ventilated-patients-with-acute-respiratory-failure-100540625","NCT06319274","Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng\u002Fkg\u002FMin) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial","COMBAT-ARF","Inclusion Criteria:\n\n* Adult intensive care patients (age ≥ 18 years)\n* Suspected pulmonary infection\n* Need for mechanical ventilation (\\\u003C 24 hours from time of screening)\n* soluble thrombomodulin (sTM) ≥ 4 ng\u002FmL in blood plasma\n\nExclusion Criteria:\n\n* Withdrawal from active therapy\n* Pregnancy (non-pregnancy confirmed by patient having a negative urine- or plasma Choriogonadotropin (hCG) or being postmenopausal defined as females at 60 years old or beyond or at the investigators discretion)\n* Septic shock according to the Sepsis 3 criteria AND a sTM\\> 10 ng\u002Fml\n* Known hypersensitivity to iloprost or to any of the other ingredients.\n* Previously included in this trial or a prostacyclin trial within 30 days\n* Life-threatening bleeding defined by the treating physician\n* Known severe heart failure (NYHA class IV)\n* Suspected acute coronary syndrome",{"count":117,"type":20},450,[119],"PHASE2","The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.",[122,123,31],"Acute Respiratory Failure","Endothelial Dysfunction",[125,126],"Endotheliopathy","SHINE","2025-08-18",{"date":129,"type":39},"2025-08-22",{"date":131,"type":39},"2024-04-15",{"date":133,"type":20},"2027-09-30",{"name":135,"class":46},"Pär Johansson",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100357438","a-prospective-registry-for-patients-with-non-tuberculous-mycobacterial-ntm-pulmonary-disease-in-korea-100357438","NCT03934034","A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.","NTM-KOREA","Inclusion Criteria:\n\n1. Clinical diagnosis of NTM pulmonary disease.\n2. The causative agent of NTM pulmonary disease includes: M. avium complex, or M. abscessus subspecies abscessus, or M. abscessus subspecies massiliense, or M. kansasii.\n3. Patients who starts new treatment (those who have previous history of treatment are eligible)\n\nExclusion Criteria\n\n1. Patients who have been treated for more than 4 weeks.\n2. The causative agent of NTM pulmonary disease is none of M. avium complex, M. abscessus subspecies abscessus, M. abscessus subspecies massiliense, or M. kansasii.","20 Years",{"count":145,"type":20},1000,"10 Years","OBSERVATIONAL","The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea. Treatment of NTM pulmonary disease is difficult and usually requires more than two years of long-term treatment, and the antibiotic regimens used in treatment vary. Therefore, it is difficult to track the natural history of patients with NTM pulmonary disease, to evaluate the treatment outcome, and to understand the effect of specific medicines on the outcome. Establishing a prospective registry of patients with NTM pulmonary disease is expected to accurately evaluate the progress, treatment modality, and treatment outcome of NTM pulmonary disease.",[150,31,151],"Pulmonary Disease","Non-Tuberculous Mycobacterial Pneumonia",[153,154,155],"NTM","Registry","Pulmonary infection","NOT_YET_RECRUITING","2019-04-30",{"date":159,"type":39},"2019-05-01",{"date":161,"type":20},"2019-04",{"date":163,"type":20},"2029-12",{"name":165,"class":46},"Seoul National University Hospital"]